SpringWorks Therapeutics, Inc. (SWTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Stamford, CT, United States. The current CEO is Saqib Islam.
SWTX has IPO date of 2019-09-13, 368 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $3.54B.
SpringWorks Therapeutics, Inc. is a biopharmaceutical company founded in 2017 that acquires, develops, and commercializes medicines targeting underserved patient populations with rare diseases and cancer. The company's lead product candidate, nirogacestat, is an oral gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors, while its clinical pipeline includes mirdametinib, a MEK inhibitor being evaluated for neurofibromatosis type 1-associated plexiform neurofibromas and solid tumors, as well as BGB-3245 for BRAF-mutant cancers. SpringWorks has established strategic collaborations and licensing agreements with major pharmaceutical companies including BeiGene, GlaxoSmithKline, Pfizer, and others to advance combination therapies and expand its therapeutic capabilities. Headquartered in Stamford, Connecticut, the company focuses on developing innovative small molecule inhibitors across multiple oncology and rare disease indications.
